Stock analysis for Cantargia AB (CANTA:Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Cantargia AB’s focus is on the development of a discovery made by Professor Thoas Fioretos and Dr Marcus Järås from Lund University. Their research showed that leukaemia stem cells express a protein on the surface called IL1RAP, which is not expressed to a large extent on normal cells. In collaboration with the founders, Cantargia has […]

Cantargia develops a therapy for the treatment of cancer by targeting a unique cell-surface receptor on malignant stem cells. Description. Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat Cantargia AB and BioInvent International AB, announced that BioInvent has been contracted as manufacturer of Cantargia's antibody CAN10 in preclinical Nov 26, 2020 PRNewswire/ -- Cantargia AB (OMXS: CANTA) and BioInvent International AB ( OMXS: BINV), today announced that BioInvent has been Mar 10, 2021 Cantargia develops antibody-based pharmaceuticals against interleukin-1 receptor accessory protein (IL1RAP). The antibody CAN04 binds I am an investor · I want to know more about Cantargia's research · I want to know more about Cantargia as a company.

Publicerad den 13 Cantargia utvecklar en antikroppsbaserad behandling riktad mot målmolekylen IL1RAP som har potential att användas för ett flertal olika cancersjukdomar. CANTARGIA AB, 556791-6019 är ett aktiebolag i Lund som registrerades år 2009 och är verksamt inom Annan naturvetenskaplig och teknisk forskning och Här samlar vi alla artiklar om Cantargia. Fler artiklar hittar du i följande artikelserier: Q2-rapporter 2017 och Börsplus podcast. Andra ämnen som ofta CANTARGIA AB. 556791-6019 (Lund). Översikt · Telefonnummer · Adresser · Styrelse och koncern · Verklig huvudman · Nyckeltal · Kreditupplysning.

Healthcare. SEK 3,168.09. Bloomberg: Reuters: Website: CANTA SS. CANTA.ST.

Cantargia AB (556791-6019). Se omsättning, bokslut, styrelse, m.m, Ladda ner gratis årsredovisningar.

Målsökande läkemedelsleverans View today's stock price, news and analysis for Cantargia AB (CANTA). Barron's also provides information on historical stock ratings, target prices, company Cantargia utvecklar en antikroppsbaserad behandling riktad mot målmolekylen IL1RAP som har potential att användas för ett flertal olika cancersjukdomar. 2021-02-15, Aktiespararna analys av Cantargia https://cantargia.com/assets/uploads/Aktiespararna-cantargia_210215.pdf. 2020-11-13, Nordea analys av Köp aktier i Cantargia - enkelt och billigt hos Avanza Bank.

Cantargia develops a therapy for the treatment of cancer by targeting a unique cell-surface receptor on malignant stem cells.

556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. {{ $select.selected.num + '. ' +$select.selected.name }}. {{ eCtrl.event.layout.

Det framgår av en analys som Vinge har företrätt Cantargia AB (publ) i samband med en riktad nyemission om 564 miljoner kronor till ett antal svenska och internationella Cantargia.
God jul o gott nytt år bilder

Detta unika "område" i diagrammet gör det möjligt att tydligt upptäcka beteendet Cantargia AB hos aktien inom de senaste 3 timmars handel, samt förse dig med viktiga data såsom daglig förändring, höga och låga kurser. Varje unit består av fyra aktier, tre teckningsoptioner av serie TO 3 samt två teckningsoptioner av serie TO 4. Teckningskurs 30,40 kr per unit.

Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The basis for this is the protein IL1RAP that is Cantargia posted a Q1 report that contained few surprises, which we take to be a positive sign that the ph IIa study for the flagship product, CAN04, is progressing according to plan.
What is the meaning of pension

på en sektorsanalys av Handelsbankens förvaltare Astrid Samuelsson. Dessutom får vi en lägesrapport från två av hennes innehav, Cantargia och Sectra.

The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform. Cantargia develops a therapy for the treatment of cancer by targeting a unique cell-surface receptor on malignant stem cells. Profile Summary. Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia.

Håkan björkman

Cantargia AB 556791-6019 23 August 2019 Cantargia and BioWa extend ongoing collaboration around the POTELLIGENT® Technology Lund, Sweden, and Princeton, NJ, USA, August 23, 2019 ---Cantargia AB and BioWa Inc. have signed an extension of the license agreement around the BioWa proprietary POTELLIGENT® Technology for

Anders Södergren, 43, om topp 15-placeringen i femmilen Expressen; Fasta, försoning och fest – så firas Ramadan i år Cantargia är ett läkemedelsbolag som utvecklar antikroppsläkemedel mot leukemi samt andra cancersjukdomar.

Cantargia AB’s focus is on the development of a discovery made by Professor Thoas Fioretos and Dr Marcus Järås from Lund University. Their research showed that leukaemia stem cells express a protein on the surface called IL1RAP, which is not expressed to a large extent on normal cells. In collaboration with the founders, Cantargia has […]

It develops CAN04, an antibody against IL1RAP to recognize cancer cells and stimulate the natural immune system to destroy such cells, as well as block the tumor inflammation.

“We are pleased to add Cantargia to our growing list of manufacturing customers, CANTA, Cantargia, (SE0006371126) 2 Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic. Note that the company may have other share series admitted to trading and that it may have unlisted shares. For complete information, please … Cantargia is a biotechnology company that specializes in the development of pharmaceuticals for various types of cancer, autoimmune and inflammatory diseases. It develops CAN04, an antibody against IL1RAP to recognize cancer cells and stimulate the natural immune system to destroy such cells, as well as block the tumor inflammation. cantargia offentliggör avsikt att genomföra riktad nyemission av aktier ons, feb 19, 2020 17:45 cet. detta pressmeddelande fÅr inte offentliggÖras, publiceras eller distribueras, helt eller delvis, direkt eller indirekt, inom eller till usa (inklusive dess territorier och besittningar, varje delstat i usa och district of columbia), australien, kanada, hongkong, israel, japan, nya zeeland Cantargia has commissioned Nordea Markets to produce a research report with the aim of providing investors with quality research on the company.